Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.

Barrios A, Rendón A, Negredo E, Barreiro P, Garcia-Benayas T, Labarga P, Santos J, Domingo P, Sánchez-Conde M, Maida I, Martín-Carbonero L, Núñez M, Blanco F, Clotet B, Sambeat MA, Gil P, Gonzalez-Lahoz J, Cooper D, Soriano V.

AIDS. 2005 Mar 24;19(6):569-75.

PMID:
15802975
2.

Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.

Negredo E, Moltó J, Burger D, Viciana P, Ribera E, Paredes R, Juan M, Ruiz L, Puig J, Pruvost A, Grassi J, Masmitjà E, Clotet B.

AIDS. 2004 Feb 20;18(3):459-63.

PMID:
15090798
3.

[Immunological effectiveness of the nucleoside/nucleotide analog combinations, tenofovir + lamivudine, didanosine + lamivudine and tenofovir + didanosine, in patients with HIV infection and sustained viral suppression].

Cervero M, Torres R, Jusdado JJ, Rodríguez-Rosado R, Del Alamo M, García-Benaya E.

Enferm Infecc Microbiol Clin. 2006 Aug-Sep;24(7):426-30. Spanish.

PMID:
16956530
4.

Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir.

Karrer U, Ledergerber B, Furrer H, Elzi L, Battegay M, Cavassini M, Gayet-Ageron A, Hirschel B, Schmid P, Russotti M, Weber R, Speck RF; Swiss HIV Cohort Study.

AIDS. 2005 Nov 18;19(17):1987-94.

PMID:
16260905
5.

Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.

Barreiro P, Soriano V.

J Antimicrob Chemother. 2006 May;57(5):806-9. Epub 2006 Mar 10.

6.

Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen.

Lacombe K, Pacanowski J, Meynard JL, Trylesinski A, Girard PM.

AIDS. 2005 Jul 1;19(10):1107-8.

PMID:
15958845
7.

Tenofovir plus didanosine as Nrti backbone in HIV-infected subjects.

Bongiovanni M, Tordato F.

Curr Med Chem. 2006;13(23):2789-93. Review.

PMID:
17073629
8.

CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.

Kakuda TN, Anderson PL, Becker SL.

AIDS. 2004 Dec 3;18(18):2442-4. No abstract available.

PMID:
15622326
9.

Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir.

García-Benayas T, Rendón AL, Rodríguez-Novóa S, Barrios A, Maida I, Blanco F, Barreiro P, Rivas P, González-Lahoz J, Soriano V.

AIDS Res Hum Retroviruses. 2006 Apr;22(4):333-7.

PMID:
16623636
10.

Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens.

Negredo E, Garrabou G, Puig J, Lòpez S, Morén C, Bellido R, Ayen R, Cardellach F, Miró O, Clotet B.

Antivir Ther. 2008;13(2):231-40. Erratum in: Antivir Ther. 2008;13(3):467.

PMID:
18505174
11.

CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.

Torti C, Lapadula G, Barreiro P, Soriano V, Mandalia S, De Silvestri A, Suter F, Maggiolo F, Antinori A, Antonucci F, Maserati R, El Hamad I, Pierotti P, Sighinolfi L, Migliorino G, Ladisa N, Carosi G; Italian MASTER Cohort.

J Antimicrob Chemother. 2007 Jun;59(6):1141-7. Epub 2007 Apr 13.

12.

Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.

Bongiovanni M, Gianotti N, Chiesa E, Nasta P, Cicconi P, Capetti A, di Biagio A, Matti A, Tirelli V, Marconi P, de Luca A, Mussini C, Gatti F, Zaccarelli M, Abeli C, Torti C, Antinori A, Castagna A, d'Arminio Monforte A.

Infection. 2007 Dec;35(6):451-6. Epub 2007 Nov 21.

PMID:
18034204
13.

In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.

Perez-Olmeda M, Garcia-Perez J, Mateos E, Spijkers S, Ayerbe MC, Carcas A, Alcami J.

J Med Virol. 2009 Feb;81(2):211-6. doi: 10.1002/jmv.21377.

PMID:
19107982
14.

The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.

Tung MY, Mandalia S, Bower M, Gazzard B, Nelson M.

HIV Med. 2005 May;6(3):151-4.

15.

Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.

Rey D, Krebs M, Partisani M, Hess G, Cheneau C, Priester M, Bernard-Henry C, de Mautort E, Lang JM.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):530-4.

PMID:
17057610
16.

Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea.

López M, Benito JM, Lozano S, Barreiro P, Martínez P, González-Lahoz J, Soriano V.

AIDS. 2004 Jun 18;18(9):1251-61.

PMID:
15362657
17.

Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients.

Pruvost A, Negredo E, Benech H, Theodoro F, Puig J, Grau E, García E, Moltó J, Grassi J, Clotet B.

Antimicrob Agents Chemother. 2005 May;49(5):1907-14.

18.

Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.

Côté HC, Magil AB, Harris M, Scarth BJ, Gadawski I, Wang N, Yu E, Yip B, Zalunardo N, Werb R, Hogg R, Harrigan PR, Montaner JS.

Antivir Ther. 2006;11(1):79-86.

PMID:
16518963
19.

Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons.

Young B, Weidle PJ, Baker RK, Armon C, Wood KC, Moorman AC, Holmberg SD; HIV Outpatient Study (HOPS) Investigators.

AIDS Patient Care STDS. 2006 Apr;20(4):238-44.

PMID:
16623622
20.

CD4+ cell count decline despite HIV suppression: a probable didanosine-valganciclovir interaction.

Tseng AL, Salit IE.

Ann Pharmacother. 2007 Mar;41(3):512-7. Epub 2007 Mar 6.

PMID:
17341536
Items per page

Supplemental Content

Write to the Help Desk